Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
24.15%
0%
24.15%
6 Months
5.78%
0%
5.78%
1 Year
17.2%
0%
17.2%
2 Years
30.8%
0%
30.8%
3 Years
6.16%
0%
6.16%
4 Years
486.0%
0%
486.0%
5 Years
318.57%
0%
318.57%
Pharming Group NV for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.67%
EBIT Growth (5y)
-15.26%
EBIT to Interest (avg)
-0.32
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.60
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.16%
ROE (avg)
7.42%
Valuation key factors
Factor
Value
P/E Ratio
768
Industry P/E
Price to Book Value
4.41
EV to EBIT
43.38
EV to EBITDA
28.76
EV to Capital Employed
4.66
EV to Sales
2.69
PEG Ratio
7.18
Dividend Yield
NA
ROCE (Latest)
10.74%
ROE (Latest)
0.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
82.20
75.20
9.31%
Operating Profit (PBDIT) excl Other Income
12.20
2.80
335.71%
Interest
4.10
4.80
-14.58%
Exceptional Items
-1.90
-7.40
74.32%
Consolidate Net Profit
4.10
-14.10
129.08%
Operating Profit Margin (Excl OI)
119.10%
4.70%
11.44%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 9.31% vs -13.46% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 129.08% vs -502.86% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
274.80
226.90
21.11%
Operating Profit (PBDIT) excl Other Income
6.80
-10.20
166.67%
Interest
9.20
5.60
64.29%
Exceptional Items
-0.00
-5.40
100.00%
Consolidate Net Profit
-10.90
-9.80
-11.22%
Operating Profit Margin (Excl OI)
-12.30%
-89.80%
7.75%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 21.11% vs 16.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -11.22% vs -175.38% in Dec 2023
About Pharming Group NV 
Pharming Group NV
Pharmaceuticals & Biotechnology
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Coordinates 
Company Details
Darwinweg 24 , LEIDEN None : 2333 CR
Registrar Details






